BF Biosciences in peak health

February 26, 2026 (MLN): BF Biosciences Limited (PSX: BFBIO) has reported a stellar financial performance for the first half of the fiscal year ending December 31, 2025, with post-tax profits climbing significantly to Rs347.3 million.

This represents a robust 77.4% increase compared to the Rs195.8 million earned during the same period last year, underpinned by a massive expansion in sales volume.

The company’s top line witnessed a dramatic surge, with Net Revenue nearly doubling (up 88%) to reach Rs5.1 billion.

While the cost of goods sold rose in tandem, BF Biosciences maintained a strong grip on its production efficiency, allowing Gross Profit to grow by 86.7% to exceed Rs2.2 billion.

The company’s gross margin stood at 43.44%, slightly lower than 43.74% recorded in the same period last year, a marginal decline of just 0.3 percentage points.

The rapid expansion came with increased operational costs; administrative and other expenses saw triple-digit percentage increases as the company scaled its infrastructure.

However, finance costs were slashed by 41.3%, dropping from Rs92.6 million to Rs54.3 million.

The bottom-line growth translated into a substantial boost for investors, with Earnings Per Share (EPS) rising to Rs3.93, up from Rs2.66 in the previous year.

The tax expense rose by 106% (from Rs126.6 million to Rs260.9 million), primarily because Profit Before Tax increased by nearly 89%. 

The effective tax rate for the period is approximately 42.9%, up from 39.3% last year.